Cormorant Asset Management, LP Spring Works Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$18.36 - $60.07 $8.72 Million - $28.5 Million	475,000 New	475,000 $11.7 Million
Q3 2021 Nov 15, 2021	SELL	$62.66 - $88.26 $939,900 - $1.32 Million	-15,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $7.42 Million - $9.42 Million	-110,000 Reduced 88.0%	15,000 $1.24 Million
Q4 2020 Feb 16, 2021	BUY	$48.36 - $77.92 $6.05 Million - $9.74 Million	125,000 New	125,000 $9.07 Million

240

69.7M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.51B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.